dc.creator | Cañada García, Javier E. | es |
dc.creator | Moure, Zaira | es |
dc.creator | Sola Campoy, Pedro J. | es |
dc.creator | Delgado-Valverde, Mercedes | es |
dc.creator | Cano, María E. | es |
dc.creator | Gijón, Desirée | es |
dc.creator | Pascual Hernández, Álvaro | es |
dc.creator | Oteo Iglesias, Jesús | es |
dc.date.accessioned | 2023-05-11T13:08:29Z | |
dc.date.available | 2023-05-11T13:08:29Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Cañada García, J.E., Moure, Z., Sola Campoy, P.J., Delgado-Valverde, M., Cano, M.E., Gijón, D.,...,Oteo Iglesias, J. (2022). CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3. Frontiers in Microbiology, 13, 918362. https://doi.org/10.3389/fmicb.2022.918362. | |
dc.identifier.issn | 1664-302X | es |
dc.identifier.uri | https://hdl.handle.net/11441/145863 | |
dc.description.abstract | Objectives: CARB-ES-19 is a comprehensive, multicenter, nationwide study integrating
whole-genome sequencing (WGS) in the surveillance of carbapenemase-producing
K. pneumoniae (CP-Kpn) and E. coli (CP-Eco) to determine their incidence, geographical
distribution, phylogeny, and resistance mechanisms in Spain.
Methods: In total, 71 hospitals, representing all 50 Spanish provinces, collected the
first 10 isolates per hospital (February to May 2019); CPE isolates were first identified
according to EUCAST (meropenem MIC > 0.12 mg/L with immunochromatography,
colorimetric tests, carbapenem inactivation, or carbapenem hydrolysis with MALDI TOF). Prevalence and incidence were calculated according to population denominators. Antibiotic susceptibility testing was performed using the microdilution method
(EUCAST). All 403 isolates collected were sequenced for high-resolution single nucleotide polymorphism (SNP) typing, core genome multilocus sequence typing
(cgMLST), and resistome analysis.
Results: In total, 377 (93.5%) CP-Kpn and 26 (6.5%) CP-Eco isolates were collected
from 62 (87.3%) hospitals in 46 (92%) provinces. CP-Kpn was more prevalent in
the blood (5.8%, 50/853) than in the urine (1.4%, 201/14,464). The cumulative
incidence for both CP-Kpn and CP-Eco was 0.05 per 100 admitted patients. The
main carbapenemase genes identified in CP-Kpn were blaOXA−48 (263/377), blaKPC−3
(62/377), blaVIM−1 (28/377), and blaNDM−1 (12/377). All isolates were susceptible
to at least two antibiotics. Interregional dissemination of eight high-risk CP-Kpn
clones was detected, mainly ST307/OXA-48 (16.4%), ST11/OXA-48 (16.4%), and
ST512-ST258/KPC (13.8%). ST512/KPC and ST15/OXA-48 were the most frequent
bacteremia-causative clones. The average number of acquired resistance genes was
higher in CP-Kpn (7.9) than in CP-Eco (5.5).
Conclusion: This study serves as a first step toward WGS integration in the surveillance
of carbapenemase-producing Enterobacterales in Spain. We detected important
epidemiological changes, including increased CP-Kpn and CP-Eco prevalence and
incidence compared to previous studies, wide interregional dissemination, and
increased dissemination of high-risk clones, such as ST307/OXA-48 and ST512/KPC-3. | es |
dc.format | application/pdf | es |
dc.format.extent | 13 p. | es |
dc.language.iso | eng | es |
dc.publisher | Frontiers Media S.A. | es |
dc.relation.ispartof | Frontiers in Microbiology, 13, 918362. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | CARB-ES-19 study | es |
dc.subject | Carbapenemases | es |
dc.subject | Whole genome sequencing | es |
dc.subject | Klebsiella pneumoniae | es |
dc.subject | High-risk clones | es |
dc.title | CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3 | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Microbiología | es |
dc.relation.projectID | PI18CIII/00030 and PI21CIII/00039 | es |
dc.relation.publisherversion | https://www.frontiersin.org/articles/10.3389/fmicb.2022.918362/full | es |
dc.identifier.doi | 10.3389/fmicb.2022.918362 | es |
dc.contributor.group | Universidad de Sevilla. CTS210: Resistencia a antimicrobianos. | es |
dc.journaltitle | Frontiers in Microbiology | es |
dc.publication.volumen | 13 | es |
dc.publication.initialPage | 918362 | es |
dc.contributor.funder | Instituto de Salud Carlos III | es |
dc.contributor.funder | Ministerio de Economía y Competitividad (MINECO). España | es |